Last edition
News about "Kite inks research pact with Appia Bio to develop "
Kite inks research pact with Appia Bio to develop allogeneic cell therapies
Kite, a Gilead Company and Appia Bio, an early stage biotechnology company, announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor
Kite Inks Research Pact With Appia Bio To Develop | 07/08/2021 | By Darshana | 165
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members